• Je něco špatně v tomto záznamu ?

Analysis of serum natalizumab concentrations obtained during routine clinical care in patients with multiple sclerosis: A cross-sectional study

D. Moskorova, I. Kacirova, P. Hradilek, P. Matlak, H. Brozmanova, P. Kusnierova, K. Licha, P. Sistik, B. Koristkova, M. Grundmann

. 2025 ; 94 (-) : 106298. [pub] 20250124

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010012

BACKGROUND: Natalizumab is a humanized monoclonal antibody administered at a fixed dose of 300 mg intravenously or subcutaneously every 4-6 weeks to treat relapsing-remitting multiple sclerosis. In this prospective cross-sectional study, natalizumab serum concentrations obtained during routine healthcare were measured, and the relationships between different routes of administration, sampling times, body characteristics, changes in blood count, and presence of anti-natalizumab antibodies were evaluated. METHODS: Ninety-two patients were included in this study. Blood samples were collected 0-48 days after administration, and natalizumab serum and anti-natalizumab antibody concentrations, as well as blood counts were measured. Subsequently, patients were divided into three groups according to the collection time after natalizumab administration. RESULTS: During the entire monitored period, serum natalizumab concentrations ranged from 1.8 to 193.3 μg/mL and 1.8 to 100.3 μg/mL after intravenous and subcutaneous administrations, respectively. A significant inverse correlation was found between serum natalizumab concentrations and differential and absolute peripheral blood neutrophil counts, erythrocyte counts, and hemoglobin concentrations. CONCLUSION: Although all patients were treated with the same dose, a 30-fold difference in serum natalizumab concentrations was observed. This wide inter-individual variability can potentially lead to an increased risk of natalizumab adverse events or, conversely, suboptimal therapeutic concentrations with the risk of further worsening of multiple sclerosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010012
003      
CZ-PrNML
005      
20250429135419.0
007      
ta
008      
250415e20250124ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.msard.2025.106298 $2 doi
035    __
$a (PubMed)39879941
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Moskorova, D $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: denisa.moskorova@fno.cz
245    10
$a Analysis of serum natalizumab concentrations obtained during routine clinical care in patients with multiple sclerosis: A cross-sectional study / $c D. Moskorova, I. Kacirova, P. Hradilek, P. Matlak, H. Brozmanova, P. Kusnierova, K. Licha, P. Sistik, B. Koristkova, M. Grundmann
520    9_
$a BACKGROUND: Natalizumab is a humanized monoclonal antibody administered at a fixed dose of 300 mg intravenously or subcutaneously every 4-6 weeks to treat relapsing-remitting multiple sclerosis. In this prospective cross-sectional study, natalizumab serum concentrations obtained during routine healthcare were measured, and the relationships between different routes of administration, sampling times, body characteristics, changes in blood count, and presence of anti-natalizumab antibodies were evaluated. METHODS: Ninety-two patients were included in this study. Blood samples were collected 0-48 days after administration, and natalizumab serum and anti-natalizumab antibody concentrations, as well as blood counts were measured. Subsequently, patients were divided into three groups according to the collection time after natalizumab administration. RESULTS: During the entire monitored period, serum natalizumab concentrations ranged from 1.8 to 193.3 μg/mL and 1.8 to 100.3 μg/mL after intravenous and subcutaneous administrations, respectively. A significant inverse correlation was found between serum natalizumab concentrations and differential and absolute peripheral blood neutrophil counts, erythrocyte counts, and hemoglobin concentrations. CONCLUSION: Although all patients were treated with the same dose, a 30-fold difference in serum natalizumab concentrations was observed. This wide inter-individual variability can potentially lead to an increased risk of natalizumab adverse events or, conversely, suboptimal therapeutic concentrations with the risk of further worsening of multiple sclerosis.
650    _2
$a lidé $7 D006801
650    12
$a natalizumab $x aplikace a dávkování $x krev $x škodlivé účinky $7 D000069442
650    _2
$a průřezové studie $7 D003430
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dospělí $7 D000328
650    12
$a imunologické faktory $x aplikace a dávkování $x škodlivé účinky $x krev $7 D007155
650    _2
$a lidé středního věku $7 D008875
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $x krev $7 D020529
650    _2
$a prospektivní studie $7 D011446
650    _2
$a mladý dospělý $7 D055815
650    _2
$a roztroušená skleróza $x farmakoterapie $x krev $7 D009103
650    _2
$a injekce subkutánní $7 D007279
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kacirova, I $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: ivana.kacirova@fno.cz
700    1_
$a Hradilek, P $u Department of Neurology, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic; Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic. Electronic address: pavel.hradilek@fno.cz
700    1_
$a Matlak, P $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: patrik.matlak@fno.cz
700    1_
$a Brozmanova, H $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: hana.brozmanova@fno.cz
700    1_
$a Kusnierova, P $u Institute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Biochemistry, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: pavlina.kusnierova@fno.cz
700    1_
$a Licha, K $u Institute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Biochemistry, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: karin.licha@fno.cz
700    1_
$a Sistik, P $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: pavel.sistik@fno.cz
700    1_
$a Koristkova, B $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: blanka.koristkova@fno.cz
700    1_
$a Grundmann, M $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic. Electronic address: milan.grundmann@osu.cz
773    0_
$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 94 (20250124), s. 106298
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39879941 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135414 $b ABA008
999    __
$a ok $b bmc $g 2311402 $s 1247093
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 94 $c - $d 106298 $e 20250124 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace